NCT06143423 - A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

AP026 (TQA2226) for injection

AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.

DRUG

AP026 (TQA2226) for injection matching placebo

AP026 (TQA2226) for injection matching placebo is a placebo produced according to AP026 (TQA2226) for injection, and has no effect on GLP-1 and FGF21.

Trial Locations (1)

130061

RECRUITING

The first hospital of Jilin University, Changchun

All Listed Sponsors

lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY